KYORIN and Novartis Sign a $832.5M Global License Agreement for KRP-M223
Shots:
- KYORIN and Novartis entered into a global license agreement for KRP-M223 and its back-up compounds discovered by KYORIN
- As per the agreement, Novartis gets an exclusive global license to develop, manufacture, and commercialize KRP-M223, where KYORIN retains an option to commercialize and manufacture product for the Japanese market, with Novartis retaining an option to co-promote with KYORIN in Japan. Additionally, KRP-M223 is in pre-clinical stage, and Novartis will handle its global development
- KYORIN will receive $55M upfront payment and up to $777.5M milestone payments based on the progress of development, approval, and commercialization of KRPM223, along with tiered royalties on net sales
Ref: KYORIN | Image: KYORIN & Novartis
Related News:- Novartis to Acquire Anthos Therapeutics for ~$3.1B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
